[{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"GluN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Cerecor"}]

Find Clinical Drug Pipeline Developments & Deals by Aevi Genomic Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.

                          Product Name : CERC-301

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 02, 2020

                          Lead Product(s) : Rislenemdaz

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Cerecor

                          Deal Size : $22.1 million

                          Deal Type : Acquisition

                          blank